<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891185</url>
  </required_header>
  <id_info>
    <org_study_id>S65525</org_study_id>
    <secondary_id>2021-002449-13</secondary_id>
    <nct_id>NCT04891185</nct_id>
  </id_info>
  <brief_title>Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer</brief_title>
  <acronym>VIPIDO</acronym>
  <official_title>Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Visualise peritoneal lesions of epithelial ovarian cancer (EOC) in both primary and interval&#xD;
      debulking surgery by using intravascular indocyanine green (ICG) and near-infrared (NIR)&#xD;
      light. This Trial wants to investigate whether ICG can increase the visibility of peritoneal&#xD;
      lesions and can differentiate between peritoneal implants and fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of correct visualisation during debulking surgery with the near-infrared (NIR) fluorescence camera of peritoneal lesions of EOC in vivo by utilising ICG.</measure>
    <time_frame>During debulking surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of diagnostic accuracy during debulking surgery with the NIR fluorescence camera of peritoneal lesions of EOC in vivo by utilising ICG.</measure>
    <time_frame>During debulking surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of lesions with positive correlation between pre-operative radiographic examination(s) and the ICG signal in vivo with the NIR fluorescence camera during surgery and immediately after surgery with the pathological examination.</measure>
    <time_frame>During debulking surgery and immediately after debulking surgery, when the pathological examination report is available.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtaining the tumour-to-background ratio of fluorescence in peritoneal lesions, lymph nodes and other anatomical structures during debulking surgery by utilising still images captures with the NIR fluorescence camera.</measure>
    <time_frame>During debulking surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the number and type of adverse effects, severe adverse effects and adverse reactions with the trial dose of the IMP during and immediately after the surgery.</measure>
    <time_frame>During debulking surgery and immediately after the surgery, up to the point in time when the pathological report is available.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Primary Debulking Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interval Debulking Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection</description>
    <arm_group_label>Interval Debulking Surgery</arm_group_label>
    <arm_group_label>Primary Debulking Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary written informed consent of the participant or their legally authorized&#xD;
             representative has been obtained prior to any screening procedures.&#xD;
&#xD;
          2. At least 18 years of age.&#xD;
&#xD;
          3. Advanced stage epithelial ovarian cancer: FIGO stage IIIb, IIIc or IV. (For FIGO&#xD;
             staging classification, please refer to Appendix 7).&#xD;
&#xD;
          4. A biopsy or cytology confirming the presence of high-grade serous epithelial ovarian&#xD;
             carcinoma&#xD;
&#xD;
          5. Preoperative imaging (CT and/or MRI), describing metastatic implants, as standard of&#xD;
             care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has a history of following diseases:&#xD;
&#xD;
               1. Hyperthyroidism&#xD;
&#xD;
               2. Autonomously functioning thyroid adenoma&#xD;
&#xD;
          2. Participant has an allergy or hypersensitivity for one or more of the following&#xD;
             components:&#xD;
&#xD;
               1. Iodine (including potassium iodine)&#xD;
&#xD;
               2. Indocyanine green&#xD;
&#xD;
          3. Any disorder, which in the Investigator's opinion might jeopardise the participant's&#xD;
             safety or compliance with the protocol.&#xD;
&#xD;
          4. Any prior or concomitant treatment(s) that might jeopardise the participant's safety&#xD;
             or that would compromise the integrity of the Trial.&#xD;
&#xD;
          5. Participation in an interventional Trial with an investigational medicinal product&#xD;
             (IMP) or device during the surgery itself.&#xD;
&#xD;
          6. Participant has a severe renal impairment (classified as renal function&lt;30&#xD;
             ml/min/1,73m2 according to CKD-EPI).&#xD;
&#xD;
          7. Participant utilises sodium bisulfite-containing heparin preparations during the day&#xD;
             before surgery. For Belgian registered drugs, this contains:&#xD;
&#xD;
               1. Danaparoid (OrgaranÂ®)&#xD;
&#xD;
               2. Other low-molecular weight heparins registered in Belgium do not contain sodium&#xD;
                  bisulfite and are not an exclusion criterion.&#xD;
&#xD;
          8. Participants requires thyroid scintigraphy utilising radioactive iodine one week after&#xD;
             surgery.&#xD;
&#xD;
          9. A previous history of major intra-abdominal surgery with potentially major adhesions&#xD;
             and/or distorted anatomy.&#xD;
&#xD;
         10. Participants utilises one of the interacting drugs listed in the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biologically female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>According to FAIR principle will data sharing be possible after conclusion of this trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

